Eli Lilly (LLY): analysis in plain words
Is Eli Lilly cheap or expensive? How it makes money, whether it grows and its risks, explained in plain words and with its official accounts.
Eli Lilly (LLY) is listed on the NYSE and we classify it in healthcare and pharma. Below are its key dated figures, how it makes money, how it compares with its sector, what works for and against Eli Lilly according to those figures, and the questions people ask most about the stock. No buy or sell tips.
Eli Lilly (LLY) key figures as of November 4, 2026
| Figure | Value | What it measures |
|---|---|---|
| Share price | $1,417.99 | Last price on November 4, 2026 |
| P/E ratio (TTM) | 46.0x | Price over earnings per share |
| Revenue growth | +38.6% | Latest quarter vs the same quarter a year earlier |
| Net margin (TTM) | 31.9% | Profit for every 100 of sales |
| Net debt / EBITDA | 1.0x | Years of operating profit to repay debt |
| Dividend yield | 0.49% | Annual dividend over price |
| Market cap | $1.26 trillion | What the stock market values it at |
The Eli Lilly figures come from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026. Any LLY figure that is not available shows as N/A: we do not estimate it.
How Eli Lilly makes money
Eli Lilly sells prescription medicines. Its largest revenue source is tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, followed by Verzenio for breast cancer, Jardiance and Trulicity for diabetes, Taltz for immunology and Kisunla for Alzheimer's disease. The United States is its biggest market.
Over the last 12 months, Eli Lilly brought in revenue of $86.5 billion. For every 100 it sells, Eli Lilly keeps 83.6 after the direct cost of what it sells (gross margin) and 53.7 after all operating costs (operating margin).
Eli Lilly against its sector
To know whether a Eli Lilly figure is high or low you have to put it next to similar companies. This table compares Eli Lilly with the median of the 30 healthcare and pharma companies Fintols covers, with data as of November 4, 2026.
| Figure | Eli Lilly | healthcare and pharma median |
|---|---|---|
| P/E | 46.0x | 31.3x (30) |
| Revenue growth | +38.6% | +8.3% (33) |
| Net margin | 31.9% | 14.9% (33) |
| Dividend yield | 0.49% | 1.52% (33) |
| Net debt / EBITDA | 1.0x | 1.6x (31) |
In short, against the typical healthcare and pharma company, Eli Lilly trades on a higher P/E, grows faster and earns a wider margin. By size, Eli Lilly ranks number 1 of 28 healthcare and pharma companies quoted in USD on Fintols.
The bull case for Eli Lilly
These are the strengths in the Eli Lilly figures as of November 4, 2026:
- Eli Lilly is selling more than a year ago: +38.6% in its latest quarter (the typical healthcare and pharma company grew +8.3%).
- Its net margin over the last 12 months is 31.9% (sector median: 14.9%): Eli Lilly turns a large share of its sales into profit.
- Analysts expect Eli Lilly earnings to rise: its P/E on the next 12 months of estimated earnings is 28.3x, below the current 46.0x.
The main risk for Eli Lilly
The price already assumes a lot: Eli Lilly trades at 46.0x its last 12 months of earnings, against 31.3x for the healthcare and pharma median. If growth disappoints, the multiple can shrink and the share price with it.
And, like the rest of healthcare and pharma, Eli Lilly is exposed to a key drug losing patent protection or a clinical trial failing, plus government pressure on prices.
Frequently asked questions about Eli Lilly
Is it a good time to buy Eli Lilly stock?
Fintols does not tell you whether to buy or sell Eli Lilly, and nobody knows what the price will do tomorrow. What we can show you is where it stands today. As of November 4, 2026, Eli Lilly stock trades at $1,417.99, 2% below its 52-week high ($1,449.68) and 67% above its low ($850.51). Its P/E is 46.0x against a healthcare and pharma median of 31.3x, and 28.3x on the earnings analysts expect over the next 12 months. With Eli Lilly, as with any stock, timing matters less than understanding the business, investing for the long run and not betting everything on a single company.
Does Eli Lilly pay a dividend?
Yes. As of November 4, 2026, Eli Lilly pays $6.92 per share a year, which at today's price is a yield of 0.49%. It uses 22% of its profit to pay it, which leaves room to keep paying it if profit dips.
Is Eli Lilly stock expensive?
It depends on what you compare it with. On P/E, Eli Lilly trades at 46.0x its last 12 months of earnings: more expensive than the healthcare and pharma median (31.3x). A high P/E alone does not make Eli Lilly expensive: it can be justified if earnings grow fast, and a low one can reflect a business in trouble.
Who are Eli Lilly's competitors?
On Fintols we compare Eli Lilly with AbbVie, Abbott and Amgen, which are also in healthcare and pharma. As of November 4, 2026, AbbVie is worth $521.0 billion and trades on a P/E of 50.7; Abbott is worth $199.9 billion and trades on a P/E of 42.9; Amgen is worth $258.7 billion and trades on a P/E of 29.7. Each has a side-by-side comparison with Eli Lilly below.
Eli Lilly competitors
- AbbVie (ABBV) analysis · Eli Lilly vs AbbVie comparison
- Abbott (ABT) analysis · Eli Lilly vs Abbott comparison
- Amgen (AMGN) analysis · Eli Lilly vs Amgen comparison
To understand Eli Lilly better
- DCF and WACC Explained: A Practical Valuation Guide
- P/E Ratio and EPS Explained: How to Read Them Without Traps
More companies like Eli Lilly: healthcare and pharma stocks, S&P 500 companies and S&P 100 companies. Open the full LLY analysis with its valuation and scenarios. Educational content about Eli Lilly, not investment advice.